Posts by Helene Kuhn

Dave sits down with Roy Davis from Immunexpress while at the JP Morgan Annual Health Conference. In this video, they discuss a new diagnostic test for detecting sepsis in patients.

Dave sits down with Roslyn Brandon from Immunexpress at the JP Morgan Annual Health Conference. In this interview, they discuss the problems of diagnosing sepsis and their innovative solution with SeptiCyte.

Seattle biotech Immunexpress is trying to raise up to $40 million in a Series C round that it plans to close by mid-year. By Rachel Nielsen.

A plenary lecture that took a journey through how we may treat sepsis in 10 years was featured with Steven Opal (Rhode Island Hospital, Providence, RI, USA) stepping up to speak about the expectations, hopes and remaining challenges in the field.

By testing white blood cells and monitoring “expression biomarkers,” SeptiCyte – a proprietary technology of Immunexpress – aims to provide faster and more accurate diagnosis of sepsis. By Gregory Zeller.

To detect sepsis quickly, says Immunexpress, track the host response, not the pathogens. By Gail Dutton.

Revolutionary diagnostic SeptiCyte™ LAB cleared by FDA for suspected sepsis patients.

The FDA granted 510(k) clearance to Immunexpress for the use of its SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis) from infection-negative (systemic inflammatory response syndrome, or SIRS) systemic inflammation in critically ill patients on their first day of intensive care unit admission.

Immunexpress earned 510(k) clearance for its RNA-based clinical diagnostic that detects sepsis in critically ill patients. The test, which uses whole blood, returns results in a few hours.

Immunexpress has won Food and Drug Administration clearance for a diagnostics test that could save hospitals billions of dollars. The FDA cleared SeptiCyte LAB analysis that tests for sepsis, a life-threatening immune response to infection.